Trevi Therapeutics says Phase 2b CORAL trial results accepted for oral presentation at CHEST 2026
Trevi Therapeutics announced Phase 2b CORAL trial results on oral nalbuphine ER were accepted for a future CHEST 2026 oral presentation. The data will be presented Oct. 20 at the CHEST 2026 Annual Meeting in Phoenix. Patient-reported outcomes indicated early, sustained improvement in chronic cough-related measures in i